Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Type 2 drugs could lower dementia, Parkinson's disease risk
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in particular.
SGLT2 inhibitors tied to lower risk of dementia, Parkinson’s disease, suggests study
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson’s disease, according to a study published in the September 18, 2024, online issue of Neurology®,
Some diabetes meds might lower risk of dementia, Parkinson's
A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, lower blood sugar by prompting the kidneys to filter sugar out of the bloodstream and excrete it in urine,
Some Diabetes Drugs May Protect Against Dementia and Parkinson's
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study
These Diabetes Drugs Could Help Lower Your Risk of Dementia, Parkinson’s
According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood glucose to improve blood sugar levels.
Some diabetes drugs tied to lower risk of dementia, Parkinson's disease
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology.
SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds.
Endocrinology Advisor
1d
SGLT2 Inhibitors Cut Kidney Risks Across CKD, Heart Failure, Diabetes Spectrum
The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.
Medscape
6d
SGLT2 Inhibitor Reduces Risk for Neurodegenerative Diseases in T2D
"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...
Daily
8d
Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits
Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
New SEC stock pricing rule
30 yrs in prison for assault
US healthcare system falls
Statue damaged by vandal
AC mayor, wife indicted
California deepfake ban
'Hidden Figures' honored
Opposes Israel arms sales
House rejects funding bill
Retaliated against scientists
Deal to build new arena
Los Angeles dengue cases
Sets new WNBA record
Completes acquisition
FL Python Challenge winner
Toy Hall of Fame finalists
Pleads not guilty
KY conversion therapy ban
Trump's New York rally
FBI disrupts hacker group
Israel strikes Hezbollah
Top Texas officials sued
US jobless claims fall
Existing home sales drop
Iran sent hacked Trump info
X back for some in Brazil
Metallica announces tour
Union opts to not endorse
To hail economic progress
Cancer deaths decline
UN backs Palestine
Related topics
Parkinson's disease
diabetes
Feedback